Expanded Access Policy
Mythic Therapeutics, has initiated a Phase 1 clinical trial to evaluate the safety, tolerability, and preliminary efficacy of MYTX-011, an antibody-drug conjugate, in patients with Non-Small Cell Lung Cancer. We understand that some patients may wish to access our investigational drug that has not yet been approved. At this stage of drug development and trials, the clinical product is being exclusively used for establishing the clinical safety and efficacy of our investigational drug. Therefore, Mythic does not currently offer an expanded access program. The most appropriate way for patients to access our investigational drug is by participating in our clinical trial, and we encourage you to speak with your doctor about whether you would qualify. Information regarding ongoing clinical trials can be accessed at www.clinicaltrials.gov.
If you have additional questions about Mythic’s expanded access policy, please speak to your physician, or contact firstname.lastname@example.org.